Russell Investments Group Ltd. Increases Holdings in Medpace Holdings, Inc. $MEDP

Russell Investments Group Ltd. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 78,509 shares of the company’s stock after buying an additional 9,536 shares during the quarter. Russell Investments Group Ltd. owned about 0.28% of Medpace worth $24,632,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. raised its position in Medpace by 20.1% in the second quarter. Jefferies Financial Group Inc. now owns 25,253 shares of the company’s stock valued at $7,926,000 after purchasing an additional 4,218 shares during the period. American Century Companies Inc. increased its position in shares of Medpace by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 12,717 shares of the company’s stock worth $3,991,000 after purchasing an additional 1,529 shares during the last quarter. Nemes Rush Group LLC increased its position in shares of Medpace by 8.3% during the 2nd quarter. Nemes Rush Group LLC now owns 628 shares of the company’s stock worth $197,000 after purchasing an additional 48 shares during the last quarter. Heron Bay Capital Management raised its holdings in Medpace by 0.3% in the 2nd quarter. Heron Bay Capital Management now owns 19,640 shares of the company’s stock valued at $6,164,000 after buying an additional 57 shares during the period. Finally, AXQ Capital LP acquired a new position in Medpace in the second quarter valued at about $217,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MEDP. Cowen reaffirmed a “sell” rating on shares of Medpace in a research report on Friday, October 24th. TD Cowen lifted their price objective on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Jefferies Financial Group increased their target price on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Truist Financial set a $555.00 price objective on Medpace in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $487.18.

Insiders Place Their Bets

In other Medpace news, Director Robert O. Kraft sold 6,472 shares of Medpace stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the completion of the sale, the director directly owned 833 shares of the company’s stock, valued at $493,011.05. The trade was a 88.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle sold 42,392 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $615.52, for a total value of $26,093,123.84. Following the transaction, the chief executive officer directly owned 732,210 shares of the company’s stock, valued at approximately $450,689,899.20. This represents a 5.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 317,597 shares of company stock valued at $189,967,248 in the last three months. Corporate insiders own 20.30% of the company’s stock.

Medpace Stock Down 1.2%

Shares of Medpace stock opened at $599.50 on Friday. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $626.26. The company has a market capitalization of $16.89 billion, a P/E ratio of 41.92, a P/E/G ratio of 2.67 and a beta of 1.42. The company has a 50 day moving average of $560.60 and a 200 day moving average of $444.37.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.